Subject Index


Acute hepatic failure, artificial supports 313 (A) Acute renal failure
- - - - arteriovenous hemodiafiltration and arteriovenous hemofiltration 33
- - - - blood purification in multiple system organ failure 295 (A)
- - - - CAVH 283 (A), 306 (A), 309 (A)
- - - - CAVH treatment after cardiac surgery 315 (A) Adolescents, treatment modalities in endstage renal disease 4 AIDS, therapeutic and safety considerations in apheresis procedures 51 Aluminum -, removal by polymethylmethacrylate membrane 286 (A) -, removal in CAPD after desferrioxamine 297 (A) Alveolar gas exchange, isovolemic hemodialysis 41 Amiodarone, treatment of induced thyreotoxicosis 293 (A) Amyloid bone cysts, development in hemodialyzed patients 308 (A) Antistaphylococcal vaccination, CAPD 312 (A) Apheresis -, familial hypercholesterolemia 298 (A)
- procedures, AIDS 51 Ascites, treatment by dialytic ultrafiltration 252 Arteriovenous dialysis fistulas, hemodynamic consequences 317 (A) Arteriovenous hemodiafiltration combined with arteriovenous hemofiltration 33 Artificial kidney membranes, cardiopulmonary effects in animal models 155 Atherosclerosis in maintenance dialysis patients 290 (A) Beta-2-microglobulin - -, adsorption on dialysis membranes 284 (A)
- -, clearances in CAVH 284 (A)
- -, effects of different dialyzers 314 (A)
- -, elimination by polyacrylonitrile hemofiltration 279 (A) -, indicator of biocompatibility 278 (A) -, kinetics and removal during hemofiltration 275 (A) -, kinetics during dialysis 307 (A) -, levels during hemodialysis 311 (A) -, predisposition to arthropathies in hemofiltration and hemodialysis 306 (A)
- -, removal during hemodiafiltration 281 (A)
- -, removal during hemofiltration 288 (A), 289 (A)
- -, removal by different membranes 279 (A), 281 (A), 286 (A), 289 (A), 305 (A), 316 (A) -, rise during hemodialysis 285 (A) Bicarbonate concentrate, microbial contamination 299 (A) Bicarbonate hemodiafiltration, acid-base balance 272 (A) Bicarbonate kinetics, paired filtration dialysis
268 (A) Bilirubin, adsorption by cholestyramine 280 (A) Biocompatibility -, artificial organs 100 -
- beta-2-microglobulin as indicator 278 (A) -, cuprophan versus hemophan 262 -, dialyzer
membranes in vitro and in vivo 317 (A) -, different hemodialysis and plasmapheresis
membranes 123 -, direct interactions of neutrophils with different
membranes 314 (A) -, membranes processes 202 -, phthalate-free hemodialysis tubings 272 (A)
Biofiltration -, acetate-free 274 (A)
- as alternative to bicarbonate dialysis 319 (A) -, continuous computerized monitoring of
hemodynamic parameters 318 (A) -, mass transfer 282 (A) Blood purification
- analysis of membrane processes 202
- hemofiltration, hemodialysis and
hemoperfusion in series 297 (A)
- in acute renal failure with multiple organ
failure 295 (A)
- short time techniques 307 (A)
- socioeconomic aspects in developing
countries 292 (A) Blood purification systems, immobilized enzymes
292 (A) Blood viscosity, erythropoietin treatment 277 (A)
Caffeine, hemodynamic effects in chronic renal
failure 276 (A) Cancer, double filtration plasmapheresis 287 (A) CAPD
- abdominal hernias 312 (A) -, aluminum removal after desferrioxamine 297(A) -,
antistaphylococcal vaccination 312 (A)
Subject Index
325
- HTLV HI antibody positive patients 308(A) -, interferon-γ and peritoneal macrophages
291(A) -, isolated ultrafiltration in diabetic nephropathy
308 (A) -, kanamycin as marker of middle-molecular solute
transport 291 (A) -, large molecule removal 280 (A) -, leukocyte tissue-type plasminogen
activator 290 (A) -, model of solute transport 316(A) -, peritoneal neutrophilia 312(A) -, positive \text{H}^+ ion
balance 299 (A) -, safer connection device 312 (A) -, vasopressin secretion 271(A)
Cardiopulmonary bypass, damaging effects 168 Cardiopulmonary effects, membranes 155
Cardiovascular function
- isovolemic hemodialysis 41
- ultrafiltration in healthy man 277 (A) Cardiovascular stability, intermittent ultrafiltration
271 (A) Catabolism, hemodialysis 303 (A) Catecholamines, hemodiafiltration 303 (A) CAVH
- acute renal failure 309 (A) -, acute renal failure after cardiac surgery 315 (A) -, functional
characteristics of hemofilters 301(A) -, increasing filter life 297 (A) -, in vitro hemodynamic
evaluation 294 (A) -, low molecular weight heparin in children
317(A) -, neonatal treatment 288 (A) -, simple device for acute renal failure 306 (A) -, suction-
supported, in children 318 (A) -, treatment of edematous states 279(A) Children, treatment
modalities in endstage renal
disease 4 Cholestyramine, bilirubin adsorption 280 (A) Ciclosporin A systemic lupus
erythematosus 271 (A) Continous arteriovenous hemofiltration, see CAPD Chronic ambulatory
peritoneal dialysis, see CAVH Cirrhosis, treatment of ascites with a hemofilter
system 252 Complement -, activation by different membranes 202, 276 (A),
288 (A), 289 (A) - activation in hemodialysis 289 (A) - activation in hemofiltration 288 (A) - activation by plasma exchange and centrifugation technique 311 (A) - artificial organs 100 - fragments in hypersensitivity reactions during hemodialysis 292 (A) - production of interleukin-1 270(A) Complement split C 3d, extracorporeal circulation 162 Complications, short-term dialysis 193 Computer modelling, hemodialysis 278 (A) Continuous arteriovenous hemodialysis - acute renal failure 283 (A) - beta-2-microglobulin clearances 284 (A) Cryofiltration, prediction of clinical response 14 Cryoglobulinemia, double-filtration plasmapheresis 300 (A) Cuprophan - biocompatibility 262 - cutaneous hypersensitivity in hemodialyzed patients 315 (A) Diabetes, hemodialysis 291 (A) Diabetic nephropathy - isolated ultrafiltration combined with CAPD 308 (A) - substantive treatment in North-Western Italy 314(A) Dialysate, bacterial contamination 284 (A) Dihydrotachysterol, immunity in hemodialyzed patients 303(A) 25-Dihydroxycholecalciferol, immunity in hemodialyzed patients 303 (A) Edema, continuous arteriovenous hemofiltration 279 (A) Endotoxinemia, bacterial contamination of dialysate 284 (A) Endotoxins - in hemodialysis patients 280 (A) - transport with high-flux membranes 202 End-stage renal disease, infants, children, adolescents 4 Erythropoietin - blood viscosity after treatment 277 (A) - treatment of anemia in hemodialyzed patients 309 (A) Ethylene oxide - antibodies in hemodialysis patients 292 (A) - cutaneous hypersensitivity in hemodialyzed patients 315 (A) Extracorporeal circulation, complement activation 162 First-use syndrome - hollow-fiber dialyzers 112 - limulus-amebocyte-lysate-reactive material 115 Furosemide, intraperitoneal application in peritoneal dialysis 270(A) 326 Subject Index

Heart failure, treatment by ultrafiltration 309 (A) Hemodialysis - beta-2-microglobulin removal 281(A) - long-term evaluation 282 (A) - plasma catecholamines and blood purification
Hemodialysis
amyloid bone cysts
analysis of membrane processes
atherosclerosis
autonomous hyperparathyroidism
beta-2-microglobulin levels and removal
blood gases and 2,3-DPG
complement activation
computer modelling
continuous computerized monitoring of hemodynamic parameters
cutaneous hypersensitivity to cuprophan and ethylene oxide
density changes and chemotactic receptors of leukocytes
depressed natural killer cell function in diabetic patients
double-lumen single needle
double complement activation
endotoxins
ethylene oxid antibodies
first-use syndrome
homeostat artificial kidney
hypersensitivity reactions
immunoglobulin levels
implantable jugular vein catheter
interleukin-1 activity
isovolemic in healthy man
jugular vein cannulation
limulus-amebocyte-lysate-reactive material
lipid peroxidation
long-term complications of short-term treatment
mass transfer
microbial contamination of bicarbonate concentrate
neutrophil chemotaxis
paired filtration dialysis with two-chamber technique
parenteral nutrition
patient’s view
phthalate-free tubings
prostaglandins
protein catabolism
racial, sexual and age discrimination
reuse and effective clearance of dialyser 296 (A)
in series with hemofiltration and hemoperfusion
297 (A)
-, short-time techniques 307 (A)
-, somatic and psychosocial prognostic indicators
287 (A) - , sterile dialysate 306 (A) - , sterile dialysate and combination with CAPD
273 (A) - , thyroid hormones and amiodarone-induced thyrotoxicosis 293 (A) - , in Turkey 286 (A)
-, urea rebound and hypercatabolism 303 (A) - , vena cave inferior diameter and optimal dry weight 293 (A) - , very low molecular weight heparin 300 (A),
301 (A) - , via a central catheter 304 (A) Hemofilter reuse, cost, safety, performance 256

Hemofiltration
-, analysis of membrane processes 202 - , beta-2-microglobulin kinetics and removal
275 (A), 279 (A), 288 (A) - , blood gases and 2,3-DPG 302 (A) - , complement activation 288 (A)
-, hemofilter reuse 256 - , in series with hemodialysis and hemoperfusion
297 (A) - , patient’s view 1 - , thyroid hormones and amiodarone-induced thyrotoxicosis 293 (A) - , treatment of cardiovascular complications
294 (A) - , urea kinetic modelling 283 (A) - , very low-molecular-weight heparin 300 (A),
301 (A) - , 9 years experience 302 (A) Hemoperfusion -, in series with hemodialysis and hemofiltration
297 (A) - , thyroid hormones and amiodarone-induced thyrotoxicosis 293 (A) Hemophan, biocompatibility 262 Hemosorption -, in end-stage renal failure and after
transplantation 301 (A) -, parameters of natural resistance 298 (A) -, rapidly progressive glomerulonephritis 298 (A) Homeostat artificial kidney, personalized dialysis
275 (A) Heparin -, low molecular weight heparin for CAVH in children 317 (A) -, side effects of low molecular weight heparin
278 (A) -, very low molecular weight heparin in hemodialysis and hemofiltration 300 (A),
301 (A)
Subject Index
327

Hollow-fiber dialyzers, first-use syndrome 112 HTLV III, positive antibodies in CAPD patients
308 (A) Hypercholesterolemia -, LDLapheresis 298 (A) -, low-density lipoprotein plasma adsorption
313 (A) Hyperparathyroidism, in hemodialysis 269 (A) Immobilized enzymes, blood purification systems
292 (A) Immunoabsorbents, in vitro testing 292 (A) Immunoglobulin, levels in hemodialyzed patients
310 (A) Infants, treatment modalities in end-stage renal disease 4 Interferon-peritonitis in CAPD patients 291 (A) Interleukin-1
-, activity in hemodialysis patients 295 (A) -, artificial organs 100 -, production using different membranes 270 (A)
Jugular vein cannulation, hemodialysis 275 (A) Jugular vein catheter, hemodialysis 315 (A) Kanamycin, middle-molecular solute transport in
CAPD 291 (A) Killer cells, function in hemodialyzed patients
305 (A)
Large molecule removal, CAPD 280 (A)
Leukocyte tissue-type plasminogen activator, activity
in CAPD 290 (A) Leukocytes -, chemotactic receptors in hemodialysis and
peritoneal dialysis 138 -, different membranes 276 (A) Limulus-amebocyte-lysate-reactive
material, first-use
syndrome in hemodialysis 115 Lipid peroxidation, in hemodialysis 296 (A) Lipoprotein plasma
adsorption, familial
hypercholesterolemia 313 (A) Lupus nephritis, plasma exchange 304 (A) Lymphocyte
proliferation, immunomodulatory effect
of specific immune complexes 311 (A)
Macrophages, peritonitis in CAPD 291 (A)
Macrosolute charge, sieving coefficient 286 (A)
Malonyldialdehyde, production in platelets 313 (A)
Membrane
-, adsorption of protein 316 (A)
-, cardiopulmonary effects in animal models 155
-, leukocytes, oxygen-free radical and complement
276 (A) -, protein catabolism 269 (A)
Membrane biocompatibility, platelet functionality
268 (A) Membrane plasmapheresis, analysis of membrane
processes 202 Membrane processes, analysis for blood purification
202
Na\textsuperscript{+}K\textsuperscript{+} pump, nuclear magnetic resonance 274 (A) Neutrophilia, CAPD patients 312 (A)
Neutrophils, chemotaxis after hemodialysis 24 Nuclear magnetic resonance, Na\textsuperscript{+}K\textsuperscript{+} pump in
uremia 274 (A)
Oxygen-free radical, production by different membranes 276 (A)
Paired filtration dialysis
-, HCO\textsubscript{3} kinetics 268 (A)
-, two-chamber technique 283 (A) Parathyroid hormone, bone formation in renal
osteodystrophy with aluminum deposition 277 (A) Parenteral nutrition, metabolic changes during
hemodialysis 281 (A) Peritoneal dialysis
-, density changes and chemotactic receptors of
leukocytes 138
-, intraperitoneal furosemide 270 (A)
-, pharmacological modulation of transport
rates 296 (A) Peritonitis, CAPD 291 (A) Phosphate, mass transfer during acetate and
bicarbonate hemodialysis 272 (A) Phthalate-free hemodialysis tubings, biocompatibility 272 (A) Plasma exchange
-, active lupus nephritis 304 (A)
-, complement activation 311 (A)
-, rapidly progressive glomerulonephritis
274 (A)
Subject Index

Polyacrylonitrile, elimination of beta-2-microglobulin 279 (A) Polyamide membrane, very effective beta-2-microglobulin removal 289 (A) Polymethylmethacrylate membrane, aluminum and beta-2-microglobulin removal 286 (A) Prostaglandins in maintenance dialysis patients 290 (A) Protein catabolism, sham dialysis with different membranes 269 (A) Protein A perfusion, basic investigations and first clinical experiences 179 Protein C, uremia 29 Rapidly progressive glomerulonephritis - , hemosorption 298 (A) - , immunosuppression and plasma exchange 274 (A) Rejection, effects of plasmapheresis 285 (A) Renal osteodystrophy, aluminum stain and parathyroid activity 277 (A) Sieving coefficient, macrosolute charge 286 (A) Single needle, daily hemodialysis 273 (A) Somatosensory evoked potentials, first dialysis 269 (A) Sterile dialysate hemodialysis, combination with CAPD 273 (A) Substitution solutions, side effects in plasma exchange 270 (A) Systemic lupus erythematosus, ciclosporin A 271 (A) Thrombotic microangiopathy, plasma exchange 310 (A) Thyroid hormones - , detoxication by plasmapheresis 304 (A) - , effects of different blood purification methods 293 (A) Ultrafiltration - , cardiovascular stability 271 (A) - , in healthy man 277 (A) - , treatment of heart failure 309 (A) Urea kinetic modelling, hemofiltration 283 (A) Uremia, defective protein C 29 Vasopressin, secretion in CAPD patients 271 (A)